Technical Analysis for AMGN - Amgen Inc.

Grade Last Price % Change Price Change
F 226.62 2.12% 4.71
AMGN closed down 0.91 percent on Thursday, March 4, 2021, on 1.43 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical AMGN trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 2.18%
Lower Bollinger Band Walk Weakness 2.18%
Outside Day Range Expansion 2.18%
Below Lower BB Weakness 2.18%
Down 3 Days in a Row Weakness 2.18%
Lower Bollinger Band Touch Weakness 2.18%
Oversold Stochastic Weakness 2.18%
Doji - Bullish? Reversal 1.26%
Lower Bollinger Band Walk Weakness 1.26%
Lower Bollinger Band Touch Weakness 1.26%
Older End-of-Day Signals for AMGN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance 3 minutes ago
Up 1 ATR 21 minutes ago
Up 2% about 1 hour ago
60 Minute Opening Range Breakout about 2 hours ago
Up 1% about 2 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Amgen Inc. Description

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Its principal products include Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body fight infections; Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases; Aranesp and EPOGEN erythropoiesis-stimulating agents that stimulate the production of red blood cells; and XGEVA/Prolia (denosumab) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides product candidates in mid- to late-stage development in various therapeutic areas comprising oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine, which includes neuroscience. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc; Takeda Pharmaceutical Company Limited; and UCB, as well as a strategic alliance with Astellas Pharma Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Biotechnology Drugs Clinics Pharmaceutical Products Bone Monoclonal Antibody Inflammation Healthcare Providers Prostate Cancer Neuroscience Hematology Therapeutic Product Inflammatory Disease Dialysis Inflammatory Diseases Wholesale Distributor Wholesale Distributors Therapeutic Products Epidermal Growth Factor Receptor Takeda Pharmaceutical Company Red Blood Cell Blood Cells Nephrology Platelet Resistant Prostate Cancer Metastases Cancer Care Growth Factors Mimics Recombinant Proteins Bone Disease Necrosis Thousand Oaks Tumor Necrosis Factor Castration Resistant Prostate Cancer Human Therapeutic Products Tumor Necrosis

Is AMGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 276.69
52 Week Low 177.05
Average Volume 2,356,655
200-Day Moving Average 237.04
50-Day Moving Average 235.55
20-Day Moving Average 231.80
10-Day Moving Average 227.66
Average True Range 5.07
ADX 19.69
+DI 17.67
-DI 22.82
Chandelier Exit (Long, 3 ATRs ) 226.73
Chandelier Exit (Short, 3 ATRs ) 235.47
Upper Bollinger Band 241.76
Lower Bollinger Band 221.84
Percent B (%b) 0.0
BandWidth 8.59
MACD Line -3.98
MACD Signal Line -2.86
MACD Histogram -1.1263
Fundamentals Value
Market Cap 129.19 Billion
Num Shares 582 Million
EPS 12.40
Price-to-Earnings (P/E) Ratio 17.90
Price-to-Sales 5.34
Price-to-Book 11.94
PEG Ratio 1.48
Dividend 6.40
Dividend Yield 2.88%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 233.34
Resistance 3 (R3) 234.05 230.96 231.43
Resistance 2 (R2) 230.96 228.05 230.60 230.80
Resistance 1 (R1) 226.44 226.25 224.89 225.72 230.16
Pivot Point 223.34 223.34 222.57 222.99 223.34
Support 1 (S1) 218.82 220.43 217.27 218.10 213.66
Support 2 (S2) 215.73 218.64 215.37 213.02
Support 3 (S3) 211.20 215.73 212.39
Support 4 (S4) 210.48